

PRESS RELEASE

25 March 2025 08:00:00 CET

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Saniona's Board and Management fully exercise their Series TO 4 warrants representing 4% of the financing

Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announces that the members of the Board of Directors and the CEO have informed the company that they will exercise all their current holdings of Series TO 4 warrants. The Board and CEO currently hold 964,334 TO 4 warrants, corresponding to SEK 4.7 million and 4.1 percent of the total issue proceeds. In March 2025, the Board members and CEO have increased their holdings by 79,635 TO 4 warrants.

This participation demonstrates the Board's and management's confidence in Saniona's strategy and their alignment with shareholders.

The exercise period for the TO 4 warrants runs until April 1, 2025, with an exercise price of SEK 4.88 per share. The outcome of the TO 4 warrant exercise will be announced on or around April 3, 2025. Complete terms and conditions for TO 4 are available on the company's website, www.saniona.com.

"I'm grateful and humbled by the Board's continued commitment and support for Saniona. Following our transformative collaboration with Acadia Pharmaceuticals in November, we have significantly strengthened our financial position. We are now focused on advancing our unique and highly promising drug candidates for neurological and psychiatric diseases to their next major inflection points, while continuing our business development efforts to secure new value-generating partnerships," said Thomas Feldthus, CEO of Saniona.

Advisers

Vator Securities AB is financial adviser and Setterwalls Advokatbyrå AB is legal adviser to the Company in connection with the exercise of TO 4. Vator Securities AB is also issuing agent in connection with the exercise of TO 4.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Saniona. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in Saniona has only been made through the prospectus published by Saniona on 18 January 2024. The prospectus has been approved and registered by the Swedish Financial Supervisory Authority and has been published on the Company's website, www.saniona.com.

Since Saniona is considered to conduct protection-worthy activities according to the Swedish Screening of Foreign Direct Investments Act (Sw. lag (2023:560) om granskning av utländska direktinvesteringar), the exercise of warrants for subscription of shares may require review by the Inspectorate of Strategic Products (ISP). More information about this can be found on the Company's website, www.saniona.com.

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

Attachments

Saniona's Board and Management fully exercise their Series TO 4 warrants representing 4% of the financing